NNIT Valuation

Q: What is the Fair Price of 0R5Z when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

0R5Z (DKK70) is trading below our estimate of [[fair value]] (DKK217.68)

Is 0R5Z undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0R5Z when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow

Simply Wall St

DKK 217.68

Fair Value

67.8% undervalued

Number of Analysts

Below Fair Value: 0R5Z (DKK70) is trading below our estimate of fair value (DKK217.68)

Significantly Below Fair Value: 0R5Z is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0R5Z?

Key metric: As 0R5Z is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0R5Z. This is calculated by dividing 0R5Z's market cap by their current revenue.
What is 0R5Z's PS Ratio?
PS Ratio	0.9x
Sales	DKK 1.85b
Market Cap	DKK 1.74b

0R5Z key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.1x
Enterprise Value/EBITDA	11.7x
PEG Ratio	26x

Price to Sales Ratio vs Peers

How does 0R5Z's PS Ratio compare to its peers?

The above table shows the PS ratio for 0R5Z vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	5.1x
OPT Optima Health	1.6x	12.21%	UK£168.7m
CRW Craneware	4.6x	8.09%	UK£689.9m
RENX Renalytix	12.5x	n/a	UK£27.3m
COG Cambridge Cognition Holdings	1.5x	17.24%	UK£15.6m
0R5Z NNIT	0.9x	6.87%	DKK 1.7b

Price-To-Sales vs Peers: 0R5Z is good value based on its Price-To-Sales Ratio (0.9x) compared to the peer average (5.1x).

Price to Sales Ratio vs Industry

How does 0R5Z's PS Ratio compare vs other companies in the European Healthcare Services Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 0R5Z is good value based on its Price-To-Sales Ratio (0.9x) compared to the European Healthcare Services industry average (1.8x).

Price to Sales Ratio vs Fair Ratio

What is 0R5Z's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0R5Z PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.9x
Fair PS Ratio	0.6x

Price-To-Sales vs Fair Ratio: 0R5Z is expensive based on its Price-To-Sales Ratio (0.9x) compared to the estimated Fair Price-To-Sales Ratio (0.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0R5Z forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	DKK 70.00	DKK 85.00 +21.43%	5.88%	DKK 90.00	DKK 80.00	n/a	2
May ’26	DKK 72.00	DKK 85.00 +18.06%	5.88%	DKK 90.00	DKK 80.00	n/a	2
Apr ’26	DKK 68.50	DKK 95.00 +38.69%	15.79%	DKK 110.00	DKK 80.00	n/a	2
Mar ’26	DKK 80.80	DKK 105.00 +29.95%	4.76%	DKK 110.00	DKK 100.00	n/a	2
Feb ’26	DKK 93.35	DKK 122.50 +31.23%	14.29%	DKK 140.00	DKK 105.00	n/a	2
Jan ’26	DKK 93.55	DKK 122.50 +30.95%	14.29%	DKK 140.00	DKK 105.00	n/a	2
Dec ’25	DKK 91.75	DKK 122.50 +33.51%	14.29%	DKK 140.00	DKK 105.00	n/a	2
Nov ’25	DKK 104.20	DKK 142.50 +36.76%	5.26%	DKK 150.00	DKK 135.00	n/a	2
Oct ’25	DKK 126.30	DKK 142.50 +12.83%	5.26%	DKK 150.00	DKK 135.00	n/a	2
Sep ’25	DKK 105.80	DKK 142.50 +34.69%	5.26%	DKK 150.00	DKK 135.00	n/a	2
Aug ’25	DKK 106.50	DKK 137.50 +29.11%	1.82%	DKK 140.00	DKK 135.00	n/a	2
Jul ’25	DKK 106.00	DKK 137.50 +29.72%	1.82%	DKK 140.00	DKK 135.00	n/a	2
Jun ’25	DKK 108.80	DKK 137.50 +26.38%	1.82%	DKK 140.00	DKK 135.00	n/a	2
May ’25	DKK 105.40	DKK 137.50 +30.46%	1.82%	DKK 140.00	DKK 135.00	DKK 72.00	2
Apr ’25	DKK 109.20	DKK 105.00 -3.85%	33.33%	DKK 140.00	DKK 70.00	DKK 68.50	2
Mar ’25	DKK 103.80	DKK 105.00 +1.16%	33.33%	DKK 140.00	DKK 70.00	DKK 80.80	2
Feb ’25	DKK 97.01	DKK 95.00 -2.07%	26.32%	DKK 120.00	DKK 70.00	DKK 93.35	2
Jan ’25	DKK 84.10	DKK 95.00 +12.97%	26.32%	DKK 120.00	DKK 70.00	DKK 93.55	2
Dec ’24	DKK 86.80	DKK 95.00 +9.45%	26.32%	DKK 120.00	DKK 70.00	DKK 91.75	2
Nov ’24	DKK 80.20	DKK 95.00 +18.46%	26.32%	DKK 120.00	DKK 70.00	DKK 104.20	2
Oct ’24	DKK 85.15	DKK 95.00 +11.57%	26.32%	DKK 120.00	DKK 70.00	DKK 126.30	2
Sep ’24	DKK 82.80	DKK 95.00 +14.73%	26.32%	DKK 120.00	DKK 70.00	DKK 105.80	2
Aug ’24	DKK 81.05	DKK 95.00 +17.21%	26.32%	DKK 120.00	DKK 70.00	DKK 106.50	2
Jul ’24	DKK 80.20	DKK 95.00 +18.45%	26.32%	DKK 120.00	DKK 70.00	DKK 106.00	2
Jun ’24	DKK 86.60	DKK 95.00 +9.70%	26.32%	DKK 120.00	DKK 70.00	DKK 108.80	2
May ’24	DKK 74.99	DKK 95.00 +26.68%	26.32%	DKK 120.00	DKK 70.00	DKK 105.40	2

AnalystConsensusTarget

Consensus Narrative from 2 Analysts

DKK 85.00

Fair Value

17.6% undervalued

Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/14 10:44
End of Day Share Price	2025/05/14 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NNIT A/S is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	ABG Sundal Collier
Niels Granholm-Leth	Carnegie Investment Bank AB
Poul Jessen	Danske Bank